US Insurers Out of Step With IBD Treatment Guidelines US Insurers Out of Step With IBD Treatment Guidelines
Most US insurance companies require patients to fail conventional therapies for Crohn ' s disease and ulcerative colitis before they will cover a biologic agent, contrary to treatment guidelines.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 14, 2024 Category: Gastroenterology Tags: Gastroenterology Source Type: news

Top-Down Treatment Superior for Crohn Disease
TUESDAY, March 5, 2024 -- Top-down treatment for Crohn disease (combination infliximab plus immunomodulator) achieves substantially better outcomes than accelerated step-up treatment, according to a study published online Feb. 22 in The Lancet... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 5, 2024 Category: Pharmaceuticals Source Type: news

Better Blockbuster-Drug Stock: Novo Nordisk vs. Eli Lilly
Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are two of the hottest pharmaceutical stocks of the past three years. Both companies have marked returns far in excess of the market's, thanks to popular demand for their freshly launched medications that treat obesity as well as type 2 diabetes.…#novonordisk #nvo #elililly #lly #ozempic #fda #zepbound #mounjaro #crohn #ozempicandwegovy (Source: Reuters: Health)
Source: Reuters: Health - March 4, 2024 Category: Consumer Health News Source Type: news

Risankizumab Beats Ustekinumab for Previously Treated Crohn's
(MedPage Today) -- Risankizumab (Skyrizi) resulted in more clinical remissions compared with ustekinumab (Stelara) in adults with moderate to severe Crohn's disease who had failed at least one previous tumor necrosis factor (TNF) inhibitor, the... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - February 26, 2024 Category: Gastroenterology Source Type: news

Why Is Teva Pharma Stock Trading Higher Today?
Friday, Alvotech ALVO and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd TEVA, announced the FDA approved Simlandi (adalimumab-ryvk) injection, as an interchangeable biosimilar to AbbVie Inc’s ABBV Humira. The biosimilar is indicated for adult rheumatoid arthritis,…#alvotech #tevapharmaceuticals #fda #abbvieincs #abbvhumira #crohn #humira #teva #tevapharma #splitspeculations (Source: Reuters: Health)
Source: Reuters: Health - February 26, 2024 Category: Consumer Health News Source Type: news

Top-Down Treatment Superior to Step-Up Approach for Crohn's Disease
(MedPage Today) -- Early and aggressive immunosuppressive therapy with tumor necrosis factor (TNF) inhibitors significantly outperformed conventional therapy for patients with newly diagnosed Crohn's disease and should become the standard for most... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - February 26, 2024 Category: Gastroenterology Source Type: news

Treating Crohn's Sooner, More Aggressively Greatly Improves Outcomes: Study
MONDAY, Feb. 26, 2024 -- In a finding that suggests sooner is better than later, a new trial shows that giving advanced treatment early to Crohn ’s patients can dramatically improve their gut health.About 80% of those who got therapy with an... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 26, 2024 Category: General Medicine Source Type: news

New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reactionThe U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergiesAllergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year1-3Basel, 25 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the N...
Source: Roche Investor Update - February 25, 2024 Category: Pharmaceuticals Source Type: news

New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reactionThe U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergiesAllergic reactions can be life-threatening and it is estimated that food-related anaphylaxis results in 30,000 medical events treated in emergency rooms in the U.S. each year1-3Basel, 25 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the N...
Source: Roche Media News - February 25, 2024 Category: Pharmaceuticals Source Type: news

Risankizumab in CD: Outcomes Remain Stable up to 3 Years Risankizumab in CD: Outcomes Remain Stable up to 3 Years
Long-term data show clinical remission and endoscopic response rates are maintained and even improve over time in patients with moderate to severe Crohn ' s disease, according to a new study.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - February 24, 2024 Category: Drugs & Pharmacology Tags: Gastroenterology Source Type: news

Capsule Endoscopy –Guided Treatment Reduces Flares in Crohn's Capsule Endoscopy –Guided Treatment Reduces Flares in Crohn's
Patients with Crohn ' s disease who are considered high-risk as determined by capsule endoscopy but are in clinical remission benefit from a treat-to-target strategy, a new study shows.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - February 23, 2024 Category: Gastroenterology Tags: Gastroenterology Source Type: news

Top headlines: Manulife backs down on Loblaw specialty drugs deal after backlash
Manulife to cover specialty drugs at any pharmacy after backlash over Loblaw deal Manulife Financial Corp. says patients who require specialty drugs will be able to fill their prescriptions at any pharmacy after backlash sparked by the insurance provider signing an exclusive arrangement with…#loblaw #loblawcos #naveedirshad #canadians #manulife #shoppersdrugmart #bayshorehealthcare #crohn #tsx #sp (Source: Reuters: Health)
Source: Reuters: Health - February 22, 2024 Category: Consumer Health News Source Type: news

FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew without an allergic reaction, compared to placeboMore than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2   Detailed OUtMATCH results will be featured in a late-breaking symposiumat the 2024 AAAAI Annual MeetingBasel, 16  February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food ...
Source: Roche Investor Update - February 16, 2024 Category: Pharmaceuticals Source Type: news

FDA approves Xolair as first and only medicine for children and adults with one or more food allergies
Approval is based on data from the NIH-sponsored Phase III OUtMATCH study, which showed a significantly higher proportion of food allergy patients as young as 1 year treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew without an allergic reaction, compared to placeboMore than 40% of children and more than half of adults with food allergies have experienced a severe reaction at least once1,2   Detailed OUtMATCH results will be featured in a late-breaking symposiumat the 2024 AAAAI Annual MeetingBasel, 16  February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food ...
Source: Roche Media News - February 16, 2024 Category: Pharmaceuticals Source Type: news

Why Bathroom Access Is a Public Health Issue
It’s not unusual to fast before a medical test to avoid skewing the results. But Dr. Zoë Gottlieb’s patients often skip meals for a different reason. Gottlieb, a gastroenterologist and assistant professor of medicine at Mount Sinai’s Icahn School of Medicine in New York City, specializes in treating inflammatory bowel disease (IBD), an umbrella term for conditions involving chronic inflammation of the gastrointestinal tract, specifically Crohn’s disease and ulcerative colitis. People with IBD have “unreliable bowel habits,” meaning they may need to use the bathroom frequently or ...
Source: TIME: Health - February 16, 2024 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthscienceclimate Source Type: news